Drew Dennison is Managing director at Lightchain Capital, LLC, the family office for Scottrade Founder and former chief executive officer Rodger Riney. At Lightchain, Dennison is responsible for venture capital investments in the life science and technology sectors.
He also assists the Riney Foundations with their philanthropic endeavors. Previously, Dennison served as the chief operating officer and chief financial officer at Scottrade Financial Services, Inc.
He led the company's operations, technology, operations, finance, and strategic planning functions and worked at the company for over a decade.
Dennison led the sale of Scottrade to TD Ameritrade, then co-led the integration project, successfully combining the two companies.
In addition, Dennison serves as chairman of the board of CareVet Holdings and as a board member of FinTech Studios.
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer.
The company's next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Arch Oncology's lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the company is advancing a number of pipeline programs, including anti-signal regulatory protein antibodies.
Arch Oncology's leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3x5 RiverVest Partners II-B, and Lightchain.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation